Lyell Immunopharma (NASDAQ:LYEL) Trading Up 13.4% – Should You Buy?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s stock price was up 13.4% on Thursday . The company traded as high as $27.27 and last traded at $27.3550. Approximately 18,234 shares traded hands during trading, a decline of 83% from the average daily volume of 108,277 shares. The stock had previously closed at $24.12.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price target for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $45.00.

Lyell Immunopharma Price Performance

The firm’s fifty day moving average is $27.14 and its two-hundred day moving average is $18.26. The firm has a market cap of $536.52 million, a price-to-earnings ratio of -1.10 and a beta of -0.13.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in shares of Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new stake in Lyell Immunopharma in the second quarter worth about $94,000. Bridgeway Capital Management LLC acquired a new stake in Lyell Immunopharma in the 2nd quarter valued at about $159,000. Walleye Capital LLC bought a new position in shares of Lyell Immunopharma during the 2nd quarter valued at about $258,000. Finally, Clarius Group LLC raised its holdings in shares of Lyell Immunopharma by 4.3% in the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock worth $324,000 after purchasing an additional 820 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.